why choose us

First received: April 13, 2023

Clinical Trial: Study of ARTS-021 in Patients With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, MTD/RP2D, and Antitumor Activity of ARTS-021 as a Single Agent and in Combination Th

Brief Summary: This study, the first clinical trial of ARTS-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of ARTS-021 in patients with advanced solid tumors.ARTS-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Read more